Rutherford Health - Withdrawal from AQSE
RNS Number : 1444Z
Rutherford Health PLC
24 January 2022
 

Rutherford Health Plc

Withdrawal from AQSE

 

24 January 2022: Rutherford Health plc (AQSE: RUTH, the "Company"), a healthcare group committed to providing innovative cancer care of the highest quality, confirms that as announced on 11 January 2022, the last day of dealing in the Company's Ordinary Shares on the AQSE Growth Market ("AQSE") will be today, 24 January 2022 and withdrawal of the Company's Ordinary Shares from trading on AQSE will take place at 08.00 on 25 January 2022.

 

For more information, please contact:

 

Rutherford Health plc


Mark Jackson, Chairman

Marcus King, Finance Director


Grant Thornton (Corporate Adviser)

Colin Aaronson / George Grainger


Instinctif Partners

Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris


Media House International

Ramsay Smith

 

 

 

About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in WalesReadingNorthumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website:  www.rutherfordhealth.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXDZGZMKGLGZZM ]]>